ASLAN004：Aspects of Atopic Dermatitis and ASLAN004 (eblasakimab)
Aspects of Atopic Dermatitis and ASLAN004 (eblasakimab)
...LeadersinDermatology'featuredaseriesofKeyOpinionLeader(KOL)eventsontheemergingAtopicDermatitis(AD)landscapeandASLAN004(eblasakimab) ...。其他文章還包含有：「ASLANPharmaceuticalsAnnouncesPositiveData...」、「ASLANPharmaceuticalscompletesphase1studyfor...」、「ASLANPharmaceuticals」、「Eblasakimab」、「NCT05158023」、「News&Publications」、「Phase2bStudyofASLAN004inAdults...」、「Phase2bStudy...
查看更多 離開網站
ASLAN Pharmaceuticals Announces Positive Data ...
https://www.biospace.com
ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a ...
ASLAN Pharmaceuticals completes phase 1 study for ...
https://aslanpharma.com
ASLAN Pharmaceuticals completes phase 1 study for ASLAN004 targeting atopic dermatitis. Today, ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), ...
ASLAN Pharmaceuticals
https://aslanpharma.com
ASLAN Pharmaceuticals is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.
Eblasakimab
https://aslanpharma.com
We hosted a series of dialogues with key opinion leaders in dermatology on the emerging Atopic Dermatitis (AD) landscape and ASLAN004 (eblasakimab).
NCT05158023
https://clinicaltrials.gov
沒有這個頁面的資訊。
News & Publications
https://aslanpharma.com
ASLAN Pharmaceuticals initiates Phase 2b study of ASLAN004 (eblasakimab) in moderate-to-severe atopic dermatitis. ASLAN Pharmaceuticals (Nasdaq: ASLN) has ...
Phase 2b Study of ASLAN004 in Adults ...
https://classic.clinicaltrials
Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are candidates ...
Phase 2b Study of ASLAN004 in Adults With Moderate
https://www.clinicaltrials.gov
Brief Summary: Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are ...